HIMS · Insider Trading
Hims & Hers Health, Inc.
Every open-market purchase and sale reported by HIMS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-15 | Soleil Boughton | Chief Legal Officer | Sell | −3,461 | −$100.58K |
| 2026-10-02 | Soleil Boughton | Chief Legal Officer | Sell | −3,461 | −$100.96K |
| 2026-10-02 | Oluyemi Okupe | Chief Financial Officer | Sell | −2,000 | −$59.40K |
| 2026-09-23 | Oluyemi Okupe | Chief Financial Officer | MIXED | −15,277 | −$806.71K |
| 2026-09-18 | Oluyemi Okupe | Chief Financial Officer | Sell | −12,313 | −$354.86K |
| 2026-09-17 | Michael Chi | Chief Operating Officer | Sell | −14,027 | −$398.23K |
| 2026-09-17 | Mohamed Elshenawy | CTO | Sell | −7,954 | −$225.81K |
| 2026-09-17 | Soleil Boughton | Chief Legal Officer | Sell | −6,236 | −$173.73K |
| 2026-09-03 | Soleil Boughton | Chief Legal Officer | Sell | −3,458 | −$97.97K |
| 2026-08-27 | Andrew Dudum | Chief Executive Officer | MIXED | −1,440,855 | — |
| 2026-08-20 | Oluyemi Okupe | Chief Financial Officer | MIXED | — | −$123.37K |
| 2026-08-20 | Deborah M. Autor | Chief Policy Officer | Sell | −16,773 | −$467.13K |
| 2026-08-20 | Soleil Boughton | Chief Legal Officer | Sell | −25,111 | −$691.81K |
| 2026-08-18 | Kare Schultz | Director | M | +6,623 | — |
| 2026-08-18 | Christopher D Payne | Director | M | +545 | — |
| 2026-08-18 | Mohamed Elshenawy | CTO | MIXED | +92,487 | −$2.70M |
| 2026-08-18 | David B Wells | Director | M | +778 | — |
| 2026-08-18 | Patrick Harrison Carroll | Chief Medical Officer | MIXED | +15,986 | −$287.16K |
| 2026-08-18 | Soleil Boughton | Chief Legal Officer | MIXED | +20,761 | −$605.23K |
| 2026-08-18 | Irene Becklund | PAO | MIXED | +7,195 | −$182.69K |
| 2026-08-18 | Oluyemi Okupe | Chief Financial Officer | MIXED | −20,204 | −$3.18M |
| 2026-08-18 | Andrew Dudum | Chief Executive Officer | MIXED | +76,134 | −$2.22M |
| 2026-08-18 | Michael Chi | Chief Operating Officer | MIXED | +38,563 | −$1.34M |
| 2026-08-18 | Deborah M. Autor | Chief Policy Officer | MIXED | +16,773 | −$454.54K |
| 2026-08-14 | Delos M. Cosgrove | Director | A | +8,223 deriv. | — |
| 2026-08-14 | Patrick Harrison Carroll | Chief Medical Officer | A | +260 deriv. | — |
| 2026-08-14 | Anja Manuel | Director | A | +8,223 deriv. | — |
| 2026-08-14 | David B Wells | Director | A | +9,001 deriv. | — |
| 2026-08-14 | Deborah M. Autor | Chief Policy Officer | A | +8,223 deriv. | — |
| 2026-08-14 | Christopher D Payne | Director | A | +8,768 deriv. | — |
| 2026-08-14 | Garcia Andrea G Perez | Director | A | +8,223 deriv. | — |
| 2026-08-14 | Kare Schultz | Director | A | +8,223 deriv. | — |
| 2026-08-14 | Kofi Owusu Amoo-Gottfried | Director | A | +21,380 deriv. | — |
| 2026-08-14 | Mohamed Elshenawy | CTO | A | +1,200,000 deriv. | — |
| 2026-07-20 | Oluyemi Okupe | Chief Financial Officer | MIXED | — | −$193.28K |
| 2026-07-07 | Oluyemi Okupe | Chief Financial Officer | MIXED | — | −$225.46K |
| 2026-06-23 | Patrick Harrison Carroll | Chief Medical Officer | Sell | −23,726 | −$830.41K |
| 2026-06-23 | Oluyemi Okupe | Chief Financial Officer | MIXED | −11,821 | −$587.27K |
| 2026-06-17 | Deborah M. Autor | Chief Policy Officer | MIXED | +17,523 | −$464.50K |
| 2026-06-17 | Mohamed Elshenawy | CTO | MIXED | +101,023 | −$5.52M |
| 2026-06-17 | Soleil Boughton | Chief Legal Officer | MIXED | +18,946 | −$703.41K |
| 2026-06-17 | Patrick Harrison Carroll | Chief Medical Officer | MIXED | +17,616 | −$250.71K |
| 2026-06-17 | Oluyemi Okupe | Chief Financial Officer | MIXED | +32,075 | −$1.19M |
| 2026-06-17 | Michael Chi | Chief Operating Officer | MIXED | +24,538 | −$1.88M |
| 2026-06-17 | Andrew Dudum | Chief Executive Officer | MIXED | +69,359 | −$2.58M |
| 2026-06-17 | Irene Becklund | PAO | MIXED | −1,962 | −$547.62K |
| 2026-06-15 | Kare Schultz | Director | M | +3,656 | — |
| 2026-06-15 | Christopher D Payne | Director | M | +14,343 | — |
| 2026-06-15 | Delos M. Cosgrove | Director | M | +3,656 | — |
| 2026-06-15 | Christiane Pendarvis | Director | M | +3,656 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Andrew Dudum | Chief Executive Officer | 1,606,379 | $45.09M |
| Melissa Baird | Chief Operating Officer | 824,630 | $23.15M |
| Michael Chi | Chief Operating Officer | 456,660 | $12.82M |
| Soleil Boughton | Chief Legal Officer | 297,348 | $8.35M |
| Oluyemi Okupe | Chief Financial Officer | 242,380 | $6.80M |
| David B Wells | Director | 229,808 | $6.45M |
| Patrick Harrison Carroll | Chief Medical Officer | 208,048 | $5.84M |
| Mohamed Elshenawy | CTO | 185,556 | $5.21M |
| Christopher D Payne | Director | 144,863 | $4.07M |
| Garcia Andrea G Perez | Director | 83,822 | $2.35M |
| Delos M. Cosgrove | Director | 67,995 | $1.91M |
| Christiane Pendarvis | Director | 55,430 | $1.56M |
| Deborah M. Autor | Chief Policy Officer | 48,961 | $1.37M |
| Anja Manuel | Director | 28,631 | $803.67K |
| Kare Schultz | Director | 26,020 | $730.38K |
| Irene Becklund | PAO | 13,985 | $392.56K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HIMS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.